Get the Stockscreener App
330.75
1.96%
6.36
After Hours:
330.60
-0.15
-0.05%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $330.75, with a volume of 2.88M.
It is up +1.96% in the last 24 hours and down -6.91% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$324.39
Open:
$323.25
24h Volume:
2.88M
Relative Volume:
1.10
Market Cap:
$178.61B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
23.00
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
-1.65%
1M Performance:
-6.91%
6M Performance:
-3.40%
1Y Performance:
+19.90%
1-Day Range:
$320.96
$332.34
1-Week Range:
$320.96
$338.00
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
330.75 | 175.17B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,021.41 | 881.12B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.00 | 551.06B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
213.76 | 369.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.44 | 284.59B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
184.64 | 285.23B | 60.48B | 10.40B | 8.05B | 3.3297 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen stock (US0311621009): FDA data and pipeline updates in focus - AD HOC NEWS
Amgen says CFO Peter Griffith to retire, names Dittrich as successor - Reuters
Amgen (AMGN) Announces CFO Transition with Peter Griffith's Reti - GuruFocus
Amgen (AMGN) Announces CFO Transition as Peter Griffith Retires - GuruFocus
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen names Thomas Dittrich as new CFO effective September By Investing.com - Investing.com Canada
AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH - PR Newswire
Is It Time To Reassess Amgen (AMGN) After Its Strong Multi Year Share Price Run - simplywall.st
Amgen stock (US0311621009): focus on obesity data and pipeline as investors await next catalysts - AD HOC NEWS
Research Alert: CFRA Keeps Buy Rating On Shares Of Amgen Inc. - 富途牛牛
Amgen Inc. stock (US0311621009): weight-loss data and earnings keep biotech in focus - AD HOC NEWS
Resona Asset Management Co. Ltd. Trims Stock Position in Amgen Inc. $AMGN - MarketBeat
Tredje AP fonden Invests $23.19 Million in Amgen Inc. $AMGN - MarketBeat
ProShare Advisors LLC Raises Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Profund Advisors LLC Increases Position in Amgen Inc. $AMGN - MarketBeat
Handelsbanken Fonder AB Sells 17,009 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Aviance Capital Partners LLC - MarketBeat
Amgen stock (US0311621009): Piper Sandler trims target after Q1 strength - AD HOC NEWS
Is Amgen Stock Poised for a Rally? - Trefis
When a Common Disease Becomes a Rare Journey: Understanding Uncontrolled Gout - Amgen
Eli Lilly Stock: Next Stop $2,000? - The Motley Fool
Gout: A type of inflammatory arthritis that may be tricky to diagnose - WJAR
Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism - Insider Monkey
Amgen Japanese Partner Urges Caution On Tavneos Use - Benzinga
Amgen Inc. stock (US0311621009): focus on Horizon integration and latest quarterly results - AD HOC NEWS
ChemoCentryx to Pay $69 Million to End Investor Lawsuit (1) - Bloomberg Law News
Amgen stock (US0311621009): obesity deal and recent approvals keep pipeline in focus - AD HOC NEWS
Amgen Stock Analysis: Repatha Surges 34% But Tax Litigation Clouds the Return Case. Here’s What to Expect - TIKR.com
TD Private Client Wealth LLC Sells 3,426 Shares of Amgen Inc. $AMGN - MarketBeat
Intratumoral Cancer Therapies Market is expected to Hit US$ - openPR.com
North Dakota State Investment Board Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) Stock Analysis: Navigating a 7.94% Potential Upside Amid Strong Dividend Yield - DirectorsTalk Interviews
GLOBALT Investments LLC GA Has $8.49 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
20 deaths: Kissei Pharmaceutical urges doctors to halt Tavneos use - 朝日新聞
Amgen Inc. stock (US0311621009): earnings beat, dividend and guidance keep biotech giant in focus - AD HOC NEWS
Amgen’s Tavneos discouraged by Japanese partner after deaths - MSN
Amgen Inc. $AMGN Shares Sold by WealthPlan Investment Management LLC - MarketBeat
Leuthold Group LLC Buys 4,396 Shares of Amgen Inc. $AMGN - MarketBeat
L & S Advisors Inc Takes Position in Amgen Inc. $AMGN - MarketBeat
iA Global Asset Management Inc. Raises Position in Amgen Inc. $AMGN - MarketBeat
STF Management LP Sells 5,198 Shares of Amgen Inc. $AMGN - MarketBeat
Northwestern Mutual Wealth Management Co. Acquires 323,064 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Canada Post Corp Registered Pension Plan - MarketBeat
Standing Bone Strong: Introducing a New Awareness Symbol for Osteoporosis - Amgen
Amgen Inc stock (US0311621009): lungs cancer setback meets steady biotech cash flow - AD HOC NEWS
Is trending stock Amgen Inc. (AMGN) a buy now? - MSN
Japan Flags 20 Deaths, Liver Injury Risk in Amgen's Rare Disease Drug Tavneos - Medical Dialogues
Amgen Inc. stock (US0311621009): focus on latest earnings and drug pipeline developments - AD HOC NEWS
Amgen (AMGN) Faces Scrutiny After Deaths Linked to Tavneos Thera - GuruFocus
Amgen’s Tavneos linked to 20 deaths in Japan (AMGN:NASDAQ) - Seeking Alpha
Stephens Inc. AR Grows Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):